ELECTROCOMPETENT CELLS MARKET ANALYSIS

Electrocompetent Cells Market, By Application (Cloning, Protein Expression, Mutagenesis, Genomic DNA Library Construction, Antibody Production, High-Throughput Screening, Others), By Cell Type (Escherichia coli (E. coli), Saccharomyces cerevisiae (S. cerevisiae), Bacillus subtilis (B. subtilis), Pseudomonas putida (P. putida), Streptococcus pneumoniae (S. pneumoniae), Others), By Transformation Efficiency (High Efficiency Cells, Ultra-High Efficiency Cells), By Packaging Format (Tubes, Plates, Custom Formats), By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments

New product launches

In July 2022, Epic-Bio, which is developing ultra-compact therapies to modulate gene expression in vivo, raised US$55 million in Series A funding.
In June 2022, REGENXBIO INC, a clinical stage biotechnology company opened its new internal facility in the U.S. to produce commercial-scale gene therapies. The company invested US$65 million to enable end-to-end control of gene therapy manufacturing at the center.
In June 2020, MaxCyte, the global cell-based drug and clinical-stage life sciences company, announced the launch of the first product in its new and expanded line of ExPERT disposables.
In January 2020, SGI-DNA, a wholly-owned subsidiary of Synthetic Genomics, Inc. (SGI), introduced VmaxTM X2, designed to produce two to four times as much soluble protein in half the time compared to traditional E. coli methods.

Acquisition and partnerships

In January 2023, MW Group and Solid Power added a research and development license as a basis for their joint next steps. This license enables BMW to build an ASSB prototype line at its Cell Manufacturing Competence Center (CMCC) in Parsdorf, near Munich.
In October 2022, Takara Bio USA, Inc., a pioneering life science reagents and instrumentation company and a wholly owned subsidiary of Takara Bio Inc., is collaborating with BioExcel Diagnostics, a clinical laboratory to develop and validate a new, comprehensive, high-throughput method for the detection of syndromic diseases.
In May 2021, New England Biolabs, Inc. (NEB), a leading provider of reagents for the life sciences, announced that it had entered into an agreement to acquire Fluorogenics Limited (FGL), a U.K.-based provider of lyophilization research and development services. Under the terms of the agreement, FGL will become a wholly owned subsidiary of NEB.